Content area

Full text

Andras Inotai [1; 2] and Marcell Csanadi [1; 3] and Guenka Petrova [4] and Maria Dimitrova [4] and Tomasz Bochenek [5] and Tomas Tesar [6] and Kristina York [7] and Leos Fuksa [8] and Alexander Kostyuk [9] and Laszlo Lorenzovici [10; 11] and Vitaly Omelyanovskiy [12] and Katalin Egyed [13] and Zoltan Kalo [1; 2]

Academic Editor: Joao Eurico Fonseca

1, Syreon Research Institute, Budapest, Hungary

2, Department of Health Policy and Health Economics, Eötvös Loránd University (ELTE), Budapest, Hungary

3, Department of Pharmaceutics and Central Clinical Pharmacy, University of Pécs, Pécs, Hungary, pte.hu

4, Faculty of Pharmacy, Medical University-Sofia, Sofia, Bulgaria, mu-sofia.bg

5, Department of Drug Management, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland, cm-uj.krakow.pl

6, Department of Organisation and Management in Pharmacy, Faculty of Pharmacy, Comenius University, Bratislava, Slovakia, uniba.sk

7, Management Center Innsbruck, Innsbruck, Austria

8, Department of Social and Clinical Pharmacy, Faculty of Pharmacy, Charles University in Prague, Hradec Králové, Czech Republic, cuni.cz

9, Kazakh Agency for Health Technology Assessment, Astana, Kazakhstan

10, Syreon Research Romania, Tirgu Mures, Romania

11, Faculty of Technical and Human Sciences, Sapientia University, Tirgu Mures, Romania

12, Center of Healthcare Quality Assessment and Control, Ministry of Health of the Russian Federation, Moscow, Russia, rosminzdrav.ru

13, Egis Pharmaceuticals, Budapest, Hungary

Received Aug 31, 2017; Accepted Dec 6, 2017

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

All European countries are facing the challenge of how to cover and reimburse high priced patent-protected medicines such as biologic treatments from their limited health care budget. Despite a greater unmet medical need due to shorter life expectancy and worse overall health status of the population compared to higher income Western European countries, financial constraints are greater in countries of Central and Eastern Europe (CEE) and Commonwealth of Independent States (CIS) [1]. However, due to external price referencing, prices of newly developed medicines are often adjusted to the price prevailing in higher income countries, and launch sequence strategies are carefully designed by manufacturers to minimize the price erosion in countries with the greatest market potential [2–4]. In contrast, the cost of health services is...
   
   
   
   
   
   
   
   
   
   

Show less